R&D | March 23, 2026
Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
